Page last updated: 2024-09-05

zm 241385 and binodenoson

zm 241385 has been researched along with binodenoson in 3 studies

Compound Research Comparison

Studies (zm 241385)	Trials (zm 241385)	Recent Studies (post-2010) (zm 241385)	Studies (binodenoson)	Trials (binodenoson)	Recent Studies (post-2010) (binodenoson)
401	3	124	16	4	4

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
de Lera Ruiz, M; Lim, YH; Zheng, J	1
Buster, BL; Linden, J; Scheld, WM; Sullivan, GW	1
Baker, SP; Belardinelli, L; Blackburn, B; Elzein, E; Gao, Z; Lasley, RD; Li, Z; Meyer, S; Palle, V; Zablocki, JA	1

Reviews

1 review(s) available for zm 241385 and binodenoson

Article	Year
Adenosine A2A receptor as a drug discovery target. Journal of medicinal chemistry, 2014, May-08, Volume: 57, Issue:9 Topics: Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Crystallography, X-Ray; Drug Discovery; Humans; Ligands; Protein Conformation; Receptor, Adenosine A2A; Signal Transduction	2014

Other Studies

2 other study(ies) available for zm 241385 and binodenoson

Article	Year
Neutrophil A2A adenosine receptor inhibits inflammation in a rat model of meningitis: synergy with the type IV phosphodiesterase inhibitor, rolipram. The Journal of infectious diseases, 1999, Volume: 180, Issue:5 Topics: Adenosine; Animals; Blood-Brain Barrier; Cell Adhesion; Cyclic AMP; Disease Models, Animal; Drug Synergism; Humans; Leukocytosis; Meningitis, Bacterial; Neutrophil Activation; Neutrophils; Phosphodiesterase Inhibitors; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Rats; Rats, Wistar; Receptor, Adenosine A2A; Receptors, Purinergic P1; Respiratory Burst; Rolipram; Superoxides; Triazines; Triazoles; Tumor Necrosis Factor-alpha	1999
Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists. The Journal of pharmacology and experimental therapeutics, 2001, Volume: 298, Issue:1 Topics: Adenosine; Animals; Antihypertensive Agents; Coronary Vessels; Corpus Striatum; Cyclic AMP; Dose-Response Relationship, Drug; Female; Humans; Male; PC12 Cells; Phenethylamines; Purinergic P1 Receptor Agonists; Purines; Pyrazoles; Rats; Receptor, Adenosine A2A; Receptors, Purinergic P1; Swine; Triazines; Triazoles; Vasodilation; Vasodilator Agents	2001

Article

Year

Neutrophil A2A adenosine receptor inhibits inflammation in a rat model of meningitis: synergy with the type IV phosphodiesterase inhibitor, rolipram.

The Journal of infectious diseases, 1999, Volume: 180, Issue:5

Topics: Adenosine; Animals; Blood-Brain Barrier; Cell Adhesion; Cyclic AMP; Disease Models, Animal; Drug Synergism; Humans; Leukocytosis; Meningitis, Bacterial; Neutrophil Activation; Neutrophils; Phosphodiesterase Inhibitors; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Rats; Rats, Wistar; Receptor, Adenosine A2A; Receptors, Purinergic P1; Respiratory Burst; Rolipram; Superoxides; Triazines; Triazoles; Tumor Necrosis Factor-alpha

1999

Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists.

The Journal of pharmacology and experimental therapeutics, 2001, Volume: 298, Issue:1

Topics: Adenosine; Animals; Antihypertensive Agents; Coronary Vessels; Corpus Striatum; Cyclic AMP; Dose-Response Relationship, Drug; Female; Humans; Male; PC12 Cells; Phenethylamines; Purinergic P1 Receptor Agonists; Purines; Pyrazoles; Rats; Receptor, Adenosine A2A; Receptors, Purinergic P1; Swine; Triazines; Triazoles; Vasodilation; Vasodilator Agents

2001